We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The HHS inspector general’s office laid out its agenda for the fiscal year, planning new and expanded reviews of the FDA’s oversight of blood establishments and laboratory-developed diagnostics; management of IT modernization initiatives; and its use of prescription drug user fees.